Person:
KAYA, PİR ALİ

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

KAYA

First Name

PİR ALİ

Name

Filters

20211
Reset filters

Settings

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Efficacy and safety of ruxolitinib in patients with myelofibrosis: A retrospective and multicenter experience in Turkey
    (Tubitak Scientific & Technological Research Council Turkey, 2021-01-01) Soyer, Nur; Ali, Ridvan; Turgut, Mehmet; Haznedaroglu, Ibrahim C.; Yilmaz, Fergun; Aydogdu, Ismet; Karakus, Volkan; Ozgur, Gokhan; Kis, Cem; Ceran, Funda; Ilhan, Gul; Ozkan, Melda; Aslaner, Muzeyyen; Ince, Idris; Yavasoglu, Irfan; Gediz, Fusun; Sonmez, Mehmet; Guvenc, Birol; Ozet, Gulsum; Kaya, Emin; Vural, Filiz; Tobu, Mahmut; Durusoy, Raika; Pir, Ali; KAYA, PİR ALİ; Vural, Filiz; Şahin, Fahri; Saydam, Guray; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; 0000-0001-5118-6894; 0000-0001-9178-2850; 0000-0001-7423-7180; 0000-0002-7798-4349; 0000-0001-6621-3138; 0000-0002-2176-4371; 0000-0001-8605-8497; 0000-0003-1041-8462; W-3827-2017; ABH-5764-2020; AAB-7711-2022; JYO-9281-2024; W-2951-2017; HRC-6282-2023; W-7916-2019; B-7408-2009; A-4238-2018
    Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28-87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10-40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 +/- 46.79 mm versus 199.49 +/- 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1-55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.